Head-to-head comparison
| Property | Mazdutide | Semaglutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Legal Status | Research Only | Prescription |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | 6.1-28.1 days (Tmax ~72 hours); extended half-life supports once-weekly dosing | ~7 days |
| Mol. Weight | — | 4,113.58 Da |
| Side Effects | Nausea, Diarrhea, Vomiting | Nausea (39%), Vomiting, Diarrhea |
Key differences
- Mechanism: Semaglutide activates GLP-1 receptors only for appetite suppression and gastric emptying delay; mazdutide additionally activates glucagon receptors, increasing hepatic fatty acid oxidation, energy expenditure, and FGF21 secretion.
- Liver fat: Mazdutide Phase 2 data showed up to 80% reduction in liver fat in some cohorts, a pronounced hepatic effect attributable to glucagon receptor agonism; semaglutide reduces liver fat primarily through weight loss rather than direct hepatic mechanisms.
- Evidence: Semaglutide has six STEP trials (10,000+ participants) and FDA approval for both T2D and obesity; mazdutide has Phase 2 data in Chinese adults and is in US Phase 2 with approximately 179 participants.
- Regulatory status: Semaglutide is FDA-approved (Ozempic, Wegovy); mazdutide is approved only in China (June 2025 for obesity, September 2025 for T2D) and has no Western regulatory approval.
- Dosing: Both are once-weekly subcutaneous injections. Semaglutide titrates to 2.4 mg; mazdutide Phase 2 most effective dose was 6 mg weekly.
- Side effects: Both cause GLP-1-class GI effects (nausea, diarrhea, vomiting). Mazdutide's glucagon component may add risk of hyperglycemia in theory, though this has been counterbalanced by GLP-1 insulinotropic effects in trial data.
- Efficacy: STEP trials showed 15-17% weight loss with semaglutide at 68 weeks; mazdutide Phase 2 showed 14.8% at 48 weeks with 6 mg dosing.
The verdict
Semaglutide is the proven standard with extensive clinical data and global regulatory approval. Mazdutide offers a differentiated mechanism through glucagon receptor activation, which produces pronounced liver fat reduction that GLP-1-only agents cannot match directly. For individuals with metabolic dysfunction-associated steatotic liver disease (MASLD), the dual mechanism is potentially significant. However, mazdutide's Western clinical evidence is limited to early-phase trials, and head-to-head data against semaglutide does not yet exist.
Frequently asked questions
Semaglutide activates only GLP-1 receptors. Mazdutide, modeled on the gut hormone oxyntomodulin, activates both GLP-1 and glucagon receptors. The glucagon component increases hepatic fatty acid oxidation and energy expenditure and induces FGF21 secretion, producing weight loss through both reduced intake and increased energy burning.
Mazdutide Phase 2 trials showed up to 80% reduction in liver fat in some cohorts, driven by direct glucagon-mediated hepatic fat clearance. Semaglutide reduces liver fat primarily as a secondary effect of overall weight loss. No head-to-head trial exists, but the mechanistic advantage of glucagon agonism for hepatic steatosis is well-supported in the pharmacology literature.
No. Mazdutide is approved in China as Xinermei for obesity and type 2 diabetes. It is in Phase 2 clinical trials in the US with approximately 179 participants enrolled. There is no compounding pharmacy or research chemical pathway for access.
Direct comparison is difficult because trials used different populations and durations. Semaglutide STEP trials showed 15-17% at 68 weeks. Mazdutide Phase 2 showed 14.8% at 48 weeks with 6 mg dosing. Longer and higher-dose mazdutide trials may yield different results, but head-to-head data is unavailable.
Both share GLP-1-class GI side effects including nausea, diarrhea, vomiting, and decreased appetite. Mazdutide additionally lists abdominal discomfort. The glucagon receptor component theoretically risks hyperglycemia, but this has been counterbalanced by the GLP-1 insulinotropic effect in published trial data.